| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* To whom correspondence should be addressed. E-mail: sbasari1{at}jhmi.edu.
Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is used in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well-known. Recent studies have also found metabolic complications in these men. Studies show that short-term ADT (3-6 months) results in development of hyperinsulinemia without causing hyperglycemia. Studies of men undergoing long-term (
12 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared to controls. In addition, men undergoing ADT also experience higher cardiovascular mortality. Long-term prospective studies of ADT are needed to determine the timing of onset of these complications and to employ strategies to prevent them. In the meantime, baseline and serial screening for fasting glucose and other cardiac risk factors in men receiving ADT is prudent. In selected cases, glucose tolerance test and cardiac evaluation may be required.
Key words: Prostate •
Androgen Deprivation •
Cardiovascular mortality •
Insulin Resistance •
Metabolic Syndrome
This article has been cited by other articles:
 |
|
 |
|
  L. J. Gooren Ethical and Medical Considerations of Androgen Deprivation Treatment of Sex Offenders J. Clin. Endocrinol. Metab., December 1, 2011; 96(12): 3628 - 3637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gillessen, A. Templeton, G. Marra, Y.-F. Kuo, E. Valtorta, and V. B. Shahinian Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer J Natl Cancer Inst, December 1, 2010; 102(23): 1760 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhasin, G. R. Cunningham, F. J. Hayes, A. M. Matsumoto, P. J. Snyder, R. S. Swerdloff, and V. M. Montori Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., June 1, 2010; 95(6): 2536 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Pinsky and W. J. G. Hellstrom Hypogonadism, ADAM, and hormone replacement Therapeutic Advances in Urology, June 1, 2010; 2(3): 99 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Traish, F. Saad, R. J. Feeley, and A. Guay The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease J Androl, September 1, 2009; 30(5): 477 - 494. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
